Allergan

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland.

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allergan plc (NYSE: AGN) between January 30, 2017 and December 19, 2018, inclusive (the “Class Period”), of the important October 29, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Allergan investors under the federal securities laws. To join the Allergan class action, go to http://www.rosenlegal.com/cases-register-1967.html

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Allergan plc Investors to Contact Firm Before Important October 29 Deadline in Class Action Seeking Recovery of Investor Losses – AGN

LOS ANGELES--(BUSINESS WIRE)---- $AGN #AGN--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allergan plc.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allergan plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $AGN #AGN--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allergan plc.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allergan plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Teva Pharmaceutical

The DFS charges claim that Teva (TEVA) and Allergan (AGN) used fraudulent marketing and promotional campaigns to promote their opioid products

Opioid Crisis Deepens as Teva, Allergan Face Fraud Charges

New York Governor Andrew Cuomo said on Tuesday the State Department of Financial Services had filed charges against Teva Pharmaceuticals and Allergan Plc over their role in the opioid crisis.

New York files insurance fraud charges against opioid makers Teva, Allergan

DUBLIN, Aug. 14, 2020 /PRNewswire/ -- The "Global Breast Implant Market: Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Global Breast Implant Market Insights 2020-2025 Featuring Allergan, Establishment Labs, GC Aesthetics, Groupe Sebbin and Others

Discovery

Discovery Communications

John Paulson (Trades, Portfolio)’s Paulson & Co. sold shares of the following stocks during the first quarter of 2020.

John Paulson Trims Allergan, Sprint, Discovery

AbbVie

AbbVie stock recently broke out and the pharmaceutical company just wrapped its acquisition of Allergan. Is AbbVie stock a buy now?

AbbVie Wraps Its $63 Billion Allergan Buyout — Is AbbVie Stock A Buy?

Allergan PLC AGN, +0.01% said late Friday that AbbVie Inc. ABBV, -0.30% has closed its acquisition of the company.

AbbVie closes acquisition of Allergan

AbbVie: Redeploy The Allergan Cash

With this final regulatory sign-off, the deal between these two pharmaceutical giants should close very soon.

AbbVie's Pending Acquisition of Allergan Earns FTC Approval

Bristol-Myers

Grifols, S.A.

Jazz Pharmaceuticals

Merck

Novo Nordisk

Sanofi

Zoetis

Pharmaceutical stocks dipped by a double-digit percentage in the first four months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.

Why These 8 Pharma Stocks Are Outplaying 90% Of The Stock Market

The deal for AbbVie Inc. ABBV, +4.28% to buy Allergan Plc. AGN, +2.16% has cleared an antitrust hurdle, the companies said late Tuesday.

Abbvie's deal for Allergan clears U.S. antitrust hurdle

On Allergan's (AGN) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

Allergan (AGN) to Report Q1 Earnings: What's in the Cards?

Don't let the pandemic distract your attention from a monster acquisition - and a chance to own AGN stock before the deal's finalized.
The post Buy Allergan Stock as Big Pharma’s Biggest Deal Is About to Close appeared first on InvestorPlace.

Buy Allergan Stock as Big Pharma’s Biggest Deal Is About to Close

Allergan (AGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Allergan (AGN) Earnings Expected to Grow: Should You Buy?

The coronavirus has completely changed the narrative on AbbVie’s buyout of AGN. Allergan stock holders banking on it should reconsider.

The AbbVie Buyout is Not a Sure Thing for Allergan Stock Investors

Abbott Labs

And two of the three offer nice dividends, too.

3 Great Stocks That Are Still Ridiculously Cheap Right Now

ARMOUR Residential REIT

Mr. Cooper Group Inc

iShares U.S. Home Construction ETF

VanEck Mortgage REIT Income ETF

VanEck Vectors Pharmaceutical ETF

TRI Pointe Group

Financial Select Sector SPDR Fund

Given recovering fundamentals, investors should take advantage of the beaten-down prices. For them, we have highlighted four solid ETF & stock picks each from the industries that are currently undervalued and have a solid Zacks Rank.

Top-Ranked ETFs & Stocks to Buy From Bargain Industries

Eli Lilly

Mylan

Pfizer

The coronavirus outbreak has made shares of top drugmakers more attractive than they've been in a quite a while.

3 Reasons Pharma Stocks Are a Buy Right Now

The blockbuster pharmaceutical deal has had its share of detractors.

AbbVie Strikes Deal With the FTC to Move Its Allergan Acquisition Forward

AbbVie Inc. ABBV, -1.68% and Allergan PLC AGN, +4.34% announced Tuesday that they signed a consent decree with the U.S.

AbbVie, Allergan sign deal with FTC to preserve merger plans

Allergan (AGN) reported earnings 30 days ago. What's next for the stock?

Allergan (AGN) Down 5.9% Since Last Earnings Report: Can It Rebound?

AbbVie stock initially fell on its $63 billion plan to buy Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

AbbVie Is Nearing Its Massive Allergan Buyout — But Is ABBV Stock A Buy?

Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma.

News for Allergan Stock (AGN)